clinical trial
Obesity significantly increases the risk of severe infection, hospitalisation, and mortality, not just long-term chronic disease
GLP-1 receptor agonists are not just making waves in weight management and diabetes care—they’re showing potential in addressing various forms of addiction. By modulating dopamine pathways in the brain, these medications could help reduce cravings and compulsive behaviours across a spectrum of addictions.
For decades, BMI has been the default measure for assessing health risks linked to weight. But while it’s easy to calculate, BMI has serious flaws—it can’t distinguish between fat and muscle, and it ignores fat distribution. Enter the Body Roundness Index (BRI), a newer metric that might finally offer a more precise look at obesity-related health risks.
In a world dominated by convenience, ultra-processed foods (UPFs) have become a staple in many diets. These foods are packaged products containing ingredients designed to extend shelf life and enhance taste. While UPFs make up 60%-70% of the US diet, their health impacts, particularly on cardiovascular disease (CVD), remain under-researched. A recent study, along with […]
There are no direct head-to-head trials between semaglutide (Wegovy) and tirzepatide (Mounjaro). So, what we have to date is like comparing two world-class boxers and asking who is the best, when they have never actually fought each other. This study uses statistical analysis to virtually “match” and “pair-up” participants in different trials to provide a better comparison of the effectiveness of the two drugs.
The SELECT trial has provided significant insights into the cardiovascular benefits of semaglutide, a GLP-1 receptor agonist, for individuals who are obese or overweight and do not have diabetes. This study aimed to determine whether semaglutide could reduce the incidence of major adverse cardiovascular events (MACE) in this population. Here’s a concise overview of the […]
Welcome, finally to Wegovy, the weight loss licensed version of Ozempic to the UK. The clinical trials have shown never before seen results with this medication.